ID ITAV_MOUSE Reviewed; 1044 AA. AC P43406; A2AKI6; DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot. DT 27-JUL-2011, sequence version 2. DT 27-MAR-2024, entry version 202. DE RecName: Full=Integrin alpha-V; DE AltName: Full=Vitronectin receptor subunit alpha; DE AltName: CD_antigen=CD51; DE Contains: DE RecName: Full=Integrin alpha-V heavy chain; DE Contains: DE RecName: Full=Integrin alpha-V light chain; DE Flags: Precursor; GN Name=Itgav; OS Mus musculus (Mouse). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; OC Murinae; Mus; Mus. OX NCBI_TaxID=10090; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RC STRAIN=CD-1; TISSUE=Kidney; RX PubMed=8601592; DOI=10.1083/jcb.132.6.1161; RA Wada J., Kumar A., Liu Z., Ruoslahti E., Reichardt L., Marvaldi J., RA Kanwar Y.S.; RT "Cloning of mouse integrin alphaV cDNA and role of the alphaV-related RT matrix receptors in metanephric development."; RL J. Cell Biol. 132:1161-1176(1996). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RC STRAIN=C57BL/6J; RX PubMed=19468303; DOI=10.1371/journal.pbio.1000112; RA Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S., She X., RA Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W., Kapustin Y., RA Meric P., Maglott D., Birtle Z., Marques A.C., Graves T., Zhou S., RA Teague B., Potamousis K., Churas C., Place M., Herschleb J., Runnheim R., RA Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z., Lindblad-Toh K., RA Eichler E.E., Ponting C.P.; RT "Lineage-specific biology revealed by a finished genome assembly of the RT mouse."; RL PLoS Biol. 7:E1000112-E1000112(2009). RN [3] RP FUNCTION, AND DISRUPTION PHENOTYPE. RX PubMed=9827803; DOI=10.1016/s0092-8674(00)81618-9; RA Bader B.L., Rayburn H., Crowley D., Hynes R.O.; RT "Extensive vasculogenesis, angiogenesis, and organogenesis precede RT lethality in mice lacking all alpha v integrins."; RL Cell 95:507-519(1998). RN [4] RP FUNCTION. RX PubMed=10025398; DOI=10.1016/s0092-8674(00)80545-0; RA Munger J.S., Huang X., Kawakatsu H., Griffiths M.J., Dalton S.L., Wu J., RA Pittet J.F., Kaminski N., Garat C., Matthay M.A., Rifkin D.B., Sheppard D.; RT "The integrin alpha v beta 6 binds and activates latent TGF beta 1: a RT mechanism for regulating pulmonary inflammation and fibrosis."; RL Cell 96:319-328(1999). RN [5] RP FUNCTION. RX PubMed=11323698; DOI=10.1038/87749; RA Castells M.C., Klickstein L.B., Hassani K., Cumplido J.A., Lacouture M.E., RA Austen K.F., Katz H.R.; RT "gp49B1-alpha(v)beta3 interaction inhibits antigen-induced mast cell RT activation."; RL Nat. Immunol. 2:436-442(2001). RN [6] RP INTERACTION WITH FBLN5. RX PubMed=11805835; DOI=10.1038/415171a; RA Nakamura T., Lozano P.R., Ikeda Y., Iwanaga Y., Hinek A., Minamisawa S., RA Cheng C.F., Kobuke K., Dalton N., Takada Y., Tashiro K., Ross J., Honjo T., RA Chien K.R.; RT "Fibulin-5/DANCE is essential for elastogenesis in vivo."; RL Nature 415:171-175(2002). RN [7] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-74; ASN-615; ASN-869 AND RP ASN-941. RC TISSUE=Myoblast; RX PubMed=19656770; DOI=10.1074/mcp.m900195-mcp200; RA Gundry R.L., Raginski K., Tarasova Y., Tchernyshyov I., Bausch-Fluck D., RA Elliott S.T., Boheler K.R., Van Eyk J.E., Wollscheid B.; RT "The mouse C2C12 myoblast cell surface N-linked glycoproteome: RT identification, glycosite occupancy, and membrane orientation."; RL Mol. Cell. Proteomics 8:2555-2569(2009). RN [8] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-74; ASN-615 AND ASN-869. RX PubMed=19349973; DOI=10.1038/nbt.1532; RA Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M., RA Schiess R., Aebersold R., Watts J.D.; RT "Mass-spectrometric identification and relative quantification of N-linked RT cell surface glycoproteins."; RL Nat. Biotechnol. 27:378-386(2009). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Brain, Brown adipose tissue, Heart, Kidney, Liver, Lung, RC Pancreas, Spleen, and Testis; RX PubMed=21183079; DOI=10.1016/j.cell.2010.12.001; RA Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R., RA Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.; RT "A tissue-specific atlas of mouse protein phosphorylation and expression."; RL Cell 143:1174-1189(2010). RN [10] RP FUNCTION. RX PubMed=24935931; DOI=10.4049/jimmunol.1302772; RA Fukao S., Haniuda K., Nojima T., Takai T., Kitamura D.; RT "gp49B-mediated negative regulation of antibody production by memory and RT marginal zone B cells."; RL J. Immunol. 193:635-644(2014). RN [11] RP FUNCTION. RX PubMed=25127859; DOI=10.4049/jimmunol.1401102; RA Edwards J.P., Thornton A.M., Shevach E.M.; RT "Release of active TGF-beta1 from the latent TGF-beta1/GARP complex on T RT regulatory cells is mediated by integrin beta8."; RL J. Immunol. 193:2843-2849(2014). CC -!- FUNCTION: The alpha-V (ITGAV) integrins are receptors for vitronectin, CC cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase- CC 2, osteopontin, osteomodulin, prothrombin, thrombospondin, TGFB1 and CC vWF (PubMed:9827803, PubMed:10025398). They recognize the sequence R-G- CC D in a wide array of ligands. Alpha-V integrins may play a role in CC embryo implantation, angiogenesis and wound healing (PubMed:9827803). CC ITGAV:ITGB3 binds to fractalkine (CX3CL1) and may act as its coreceptor CC in CX3CR1-dependent fractalkine signaling (By similarity). ITGAV:ITGB3 CC binds to NRG1 (via EGF domain) and this binding is essential for NRG1- CC ERBB signaling. ITGAV:ITGB3 binds to FGF1 and this binding is essential CC for FGF1 signaling (By similarity). ITGAV:ITGB3 binds to FGF2 and this CC binding is essential for FGF2 signaling (By similarity). ITGAV:ITGB3 CC binds to IGF1 and this binding is essential for IGF1 signaling (By CC similarity). ITGAV:ITGB3 binds to IGF2 and this binding is essential CC for IGF2 signaling (By similarity). ITGAV:ITGB3 binds to IL1B and this CC binding is essential for IL1B signaling (By similarity). ITGAV:ITGB3 CC binds to PLA2G2A via a site (site 2) which is distinct from the CC classical ligand-binding site (site 1) and this induces integrin CC conformational changes and enhanced ligand binding to site 1 (By CC similarity). ITGAV:ITGB3 and ITGAV:ITGB6 act as a receptor for CC fibrillin-1 (FBN1) and mediate R-G-D-dependent cell adhesion to FBN1 CC (By similarity). Integrin alpha-V/beta-6 or alpha-V/beta-8 (ITGAV:ITGB6 CC or ITGAV:ITGB8) mediates R-G-D-dependent release of transforming growth CC factor beta-1 (TGF-beta-1) from regulatory Latency-associated peptide CC (LAP), thereby playing a key role in TGF-beta-1 activation CC (PubMed:10025398, PubMed:25127859). ITGAV:ITGB3 acts as a receptor for CC CD40LG (By similarity). ITGAV:ITGB3 binds to the Lilrb4a/Gp49b receptor CC and enhances the Lilrb4a-mediated inhibition of mast cell activation CC (PubMed:11323698). ITGAV:ITGB3 also suppresses marginal zone B cell CC antibody production through its interaction with Lilrb4a CC (PubMed:24935931). ITGAV:ITGB3 acts as a receptor for IBSP and promotes CC cell adhesion and migration to IBSP (By similarity). CC {ECO:0000250|UniProtKB:P06756, ECO:0000269|PubMed:10025398, CC ECO:0000269|PubMed:11323698, ECO:0000269|PubMed:24935931, CC ECO:0000269|PubMed:25127859, ECO:0000269|PubMed:9827803}. CC -!- SUBUNIT: Heterodimer of an alpha and a beta subunit. The alpha subunit CC is composed of a heavy and a light chain linked by a disulfide bond. CC Alpha-V (ITGAV) associates with either beta-1 (ITGB1), beta-3 (ITGB3), CC beta-5 (ITGB5), beta-6 (ITGB6) or beta-8 (ITGB8) (Probable). Interacts CC with RAB25. Interacts with CIB1 (By similarity). Integrins ITGAV:ITGB3 CC and ITGAV:ITGB5 interact with FBLN5 (via N-terminus) (PubMed:11805835). CC ITGAV:ITGB3 and ITGAV:ITGB5 interact with CCN3 (By similarity). CC ITGAV:ITGB3 interacts with ADGRA2 (By similarity). ITGAV:ITGB3 CC interacts with FGF2; it is likely that FGF2 can simultaneously bind CC ITGAV:ITGB3 and FGF receptors (By similarity). ITGAV:ITGB3 is found in CC a ternary complex with CX3CR1 and CX3CL1. ITGAV:ITGB3 is found in a CC ternary complex with NRG1 and ERBB3. ITGAV:ITGB3 is found in a ternary CC complex with FGF1 and FGFR1. ITGAV:ITGB3 is found in a ternary complex CC with IGF1 and IGF1R (By similarity). ITGAV:ITGB3 interacts with IGF2 CC (By similarity). ITGAV:ITGB3 and ITGAV:ITGB6 interact with FBN1 (By CC similarity). ITGAV:ITGB3 interacts with CD9, CD81 and CD151 (via second CC extracellular domain) (By similarity). ITGAV:ITGB6 interacts with TGFB1 CC (PubMed:10025398). ITGAV:ITGB3 interacts with PTN. Forms a complex with CC PTPRZ1 and PTN that stimulates endothelial cell migration through ITGB3 CC 'Tyr-773' phosphorylation (By similarity). CC {ECO:0000250|UniProtKB:P06756, ECO:0000269|PubMed:10025398, CC ECO:0000269|PubMed:11805835, ECO:0000305|PubMed:11805835}. CC -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane CC protein. Cell junction, focal adhesion {ECO:0000250|UniProtKB:P06756}. CC -!- DISRUPTION PHENOTYPE: Mice expressing a null mutation of the alpha-V CC subunit gene survive until late in embryonic development and CC occasionally even to birth. They demonstrate cleft palate, and CC defective development of CNS and gastrointestinal blood vessels. CC {ECO:0000269|PubMed:9827803}. CC -!- SIMILARITY: Belongs to the integrin alpha chain family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U14135; AAC52497.1; -; mRNA. DR EMBL; AL772301; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS16181.1; -. DR PIR; T10050; T10050. DR RefSeq; NP_032428.2; NM_008402.3. DR AlphaFoldDB; P43406; -. DR SMR; P43406; -. DR BioGRID; 200824; 4. DR ComplexPortal; CPX-3035; Integrin alphav-beta3 complex. DR ComplexPortal; CPX-3130; Integrin alphav-beta1 complex. DR ComplexPortal; CPX-3131; Integrin alphav-beta5 complex. DR ComplexPortal; CPX-3132; Integrin alphav-beta6 complex. DR ComplexPortal; CPX-3133; Integrin alphav-beta8 complex. DR CORUM; P43406; -. DR IntAct; P43406; 3. DR STRING; 10090.ENSMUSP00000028499; -. DR BindingDB; P43406; -. DR ChEMBL; CHEMBL3430891; -. DR ChEMBL; CHEMBL4523628; -. DR GlyConnect; 2402; 13 N-Linked glycans (5 sites). DR GlyCosmos; P43406; 12 sites, 13 glycans. DR GlyGen; P43406; 13 sites, 13 N-linked glycans (5 sites), 1 O-linked glycan (1 site). DR iPTMnet; P43406; -. DR PhosphoSitePlus; P43406; -. DR SwissPalm; P43406; -. DR EPD; P43406; -. DR jPOST; P43406; -. DR MaxQB; P43406; -. DR PaxDb; 10090-ENSMUSP00000028499; -. DR PeptideAtlas; P43406; -. DR ProteomicsDB; 268896; -. DR Pumba; P43406; -. DR ABCD; P43406; 12 sequenced antibodies. DR Antibodypedia; 1498; 1722 antibodies from 47 providers. DR DNASU; 16410; -. DR Ensembl; ENSMUST00000028499.11; ENSMUSP00000028499.5; ENSMUSG00000027087.12. DR GeneID; 16410; -. DR KEGG; mmu:16410; -. DR UCSC; uc008kid.2; mouse. DR AGR; MGI:96608; -. DR CTD; 3685; -. DR MGI; MGI:96608; Itgav. DR VEuPathDB; HostDB:ENSMUSG00000027087; -. DR eggNOG; KOG3637; Eukaryota. DR GeneTree; ENSGT00940000158361; -. DR HOGENOM; CLU_004111_4_0_1; -. DR InParanoid; P43406; -. DR OMA; YILHYEV; -. DR OrthoDB; 3816176at2759; -. DR PhylomeDB; P43406; -. DR TreeFam; TF105391; -. DR Reactome; R-MMU-1236973; Cross-presentation of particulate exogenous antigens (phagosomes). DR Reactome; R-MMU-1566948; Elastic fibre formation. DR Reactome; R-MMU-210990; PECAM1 interactions. DR Reactome; R-MMU-2129379; Molecules associated with elastic fibres. DR Reactome; R-MMU-216083; Integrin cell surface interactions. DR Reactome; R-MMU-2173789; TGF-beta receptor signaling activates SMADs. DR Reactome; R-MMU-3000170; Syndecan interactions. DR Reactome; R-MMU-3000178; ECM proteoglycans. DR Reactome; R-MMU-4420097; VEGFA-VEGFR2 Pathway. DR Reactome; R-MMU-445144; Signal transduction by L1. DR Reactome; R-MMU-6798695; Neutrophil degranulation. DR BioGRID-ORCS; 16410; 18 hits in 82 CRISPR screens. DR ChiTaRS; Itgav; mouse. DR PRO; PR:P43406; -. DR Proteomes; UP000000589; Chromosome 2. DR RNAct; P43406; Protein. DR Bgee; ENSMUSG00000027087; Expressed in cumulus cell and 282 other cell types or tissues. DR ExpressionAtlas; P43406; baseline and differential. DR GO; GO:0035868; C:alphav-beta3 integrin-HMGB1 complex; ISO:MGI. DR GO; GO:0035867; C:alphav-beta3 integrin-IGF-1-IGF1R complex; ISO:MGI. DR GO; GO:0009986; C:cell surface; ISS:BHF-UCL. DR GO; GO:0005829; C:cytosol; ISO:MGI. DR GO; GO:0009897; C:external side of plasma membrane; IDA:MGI. DR GO; GO:0031527; C:filopodium membrane; ISO:MGI. DR GO; GO:0005925; C:focal adhesion; ISS:UniProtKB. DR GO; GO:0034682; C:integrin alphav-beta1 complex; IEA:Ensembl. DR GO; GO:0034683; C:integrin alphav-beta3 complex; ISO:MGI. DR GO; GO:0034684; C:integrin alphav-beta5 complex; IDA:BHF-UCL. DR GO; GO:0034685; C:integrin alphav-beta6 complex; IDA:CAFA. DR GO; GO:0034686; C:integrin alphav-beta8 complex; ISS:UniProtKB. DR GO; GO:0008305; C:integrin complex; ISS:BHF-UCL. DR GO; GO:0031258; C:lamellipodium membrane; ISO:MGI. DR GO; GO:0016020; C:membrane; IDA:BHF-UCL. DR GO; GO:0031528; C:microvillus membrane; ISO:MGI. DR GO; GO:0005886; C:plasma membrane; IDA:MGI. DR GO; GO:0032587; C:ruffle membrane; ISO:MGI. DR GO; GO:0019960; F:C-X3-C chemokine binding; IEA:Ensembl. DR GO; GO:0050840; F:extracellular matrix binding; ISO:MGI. DR GO; GO:1990430; F:extracellular matrix protein binding; ISO:MGI. DR GO; GO:0017134; F:fibroblast growth factor binding; IEA:Ensembl. DR GO; GO:0001968; F:fibronectin binding; ISO:MGI. DR GO; GO:0031994; F:insulin-like growth factor I binding; IEA:Ensembl. DR GO; GO:0005178; F:integrin binding; IPI:BHF-UCL. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0038132; F:neuregulin binding; IEA:Ensembl. DR GO; GO:0002020; F:protease binding; ISO:MGI. DR GO; GO:0005102; F:signaling receptor binding; ISO:MGI. DR GO; GO:0050431; F:transforming growth factor beta binding; ISS:BHF-UCL. DR GO; GO:0005245; F:voltage-gated calcium channel activity; ISO:MGI. DR GO; GO:0001525; P:angiogenesis; IBA:GO_Central. DR GO; GO:0038027; P:apolipoprotein A-I-mediated signaling pathway; ISO:MGI. DR GO; GO:0043277; P:apoptotic cell clearance; IDA:BHF-UCL. DR GO; GO:0001568; P:blood vessel development; IMP:MGI. DR GO; GO:0070588; P:calcium ion transmembrane transport; ISO:MGI. DR GO; GO:0007155; P:cell adhesion; ISS:BHF-UCL. DR GO; GO:0033627; P:cell adhesion mediated by integrin; IDA:CAFA. DR GO; GO:0016477; P:cell migration; ISO:MGI. DR GO; GO:0098609; P:cell-cell adhesion; IBA:GO_Central. DR GO; GO:0007160; P:cell-matrix adhesion; ISO:MGI. DR GO; GO:0031589; P:cell-substrate adhesion; ISO:MGI. DR GO; GO:0032490; P:detection of molecule of bacterial origin; TAS:BHF-UCL. DR GO; GO:0035987; P:endodermal cell differentiation; ISO:MGI. DR GO; GO:0043542; P:endothelial cell migration; TAS:BHF-UCL. DR GO; GO:0070371; P:ERK1 and ERK2 cascade; IDA:BHF-UCL. DR GO; GO:0097192; P:extrinsic apoptotic signaling pathway in absence of ligand; IDA:BHF-UCL. DR GO; GO:0009566; P:fertilization; NAS:BHF-UCL. DR GO; GO:0048041; P:focal adhesion assembly; NAS:BHF-UCL. DR GO; GO:0035262; P:gonad morphogenesis; NAS:BHF-UCL. DR GO; GO:0034113; P:heterotypic cell-cell adhesion; ISO:MGI. DR GO; GO:0006954; P:inflammatory response; TAS:BHF-UCL. DR GO; GO:0007229; P:integrin-mediated signaling pathway; ISO:MGI. DR GO; GO:0050919; P:negative chemotaxis; ISO:MGI. DR GO; GO:2000536; P:negative regulation of entry of bacterium into host cell; ISS:BHF-UCL. DR GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; ISO:MGI. DR GO; GO:0010888; P:negative regulation of lipid storage; ISS:BHF-UCL. DR GO; GO:0032369; P:negative regulation of lipid transport; ISS:BHF-UCL. DR GO; GO:0050748; P:negative regulation of lipoprotein metabolic process; ISS:BHF-UCL. DR GO; GO:1905598; P:negative regulation of low-density lipoprotein receptor activity; ISS:BHF-UCL. DR GO; GO:0010745; P:negative regulation of macrophage derived foam cell differentiation; ISS:BHF-UCL. DR GO; GO:0045785; P:positive regulation of cell adhesion; ISS:BHF-UCL. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:BHF-UCL. DR GO; GO:0008284; P:positive regulation of cell population proliferation; ISS:BHF-UCL. DR GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; ISO:MGI. DR GO; GO:1902533; P:positive regulation of intracellular signal transduction; ISO:MGI. DR GO; GO:0033690; P:positive regulation of osteoblast proliferation; IMP:BHF-UCL. DR GO; GO:0051057; P:positive regulation of small GTPase mediated signal transduction; ISO:MGI. DR GO; GO:0045124; P:regulation of bone resorption; TAS:BHF-UCL. DR GO; GO:0050764; P:regulation of phagocytosis; ISS:BHF-UCL. DR GO; GO:1901388; P:regulation of transforming growth factor beta activation; ISS:UniProtKB. DR GO; GO:0051209; P:release of sequestered calcium ion into cytosol; TAS:BHF-UCL. DR GO; GO:0071731; P:response to nitric oxide; TAS:BHF-UCL. DR GO; GO:0034446; P:substrate adhesion-dependent cell spreading; ISO:MGI. DR GO; GO:0042110; P:T cell activation; TAS:BHF-UCL. DR GO; GO:0071604; P:transforming growth factor beta production; IDA:CAFA. DR GO; GO:0060707; P:trophoblast giant cell differentiation; TAS:BHF-UCL. DR GO; GO:0001570; P:vasculogenesis; IEA:Ensembl. DR GO; GO:0046718; P:viral entry into host cell; ISO:MGI. DR Gene3D; 1.20.5.930; Bicelle-embedded integrin alpha(iib) transmembrane segment; 1. DR Gene3D; 2.130.10.130; Integrin alpha, N-terminal; 1. DR Gene3D; 2.60.40.1460; Integrin domains. Chain A, domain 2; 1. DR Gene3D; 2.60.40.1510; ntegrin, alpha v. Chain A, domain 3; 1. DR Gene3D; 2.60.40.1530; ntegrin, alpha v. Chain A, domain 4; 1. DR InterPro; IPR013517; FG-GAP. DR InterPro; IPR013519; Int_alpha_beta-p. DR InterPro; IPR000413; Integrin_alpha. DR InterPro; IPR018184; Integrin_alpha_C_CS. DR InterPro; IPR013649; Integrin_alpha_Ig-like_1. DR InterPro; IPR048285; Integrin_alpha_Ig-like_2. DR InterPro; IPR048286; Integrin_alpha_Ig-like_3. DR InterPro; IPR028994; Integrin_alpha_N. DR InterPro; IPR032695; Integrin_dom_sf. DR PANTHER; PTHR23220; INTEGRIN ALPHA; 1. DR PANTHER; PTHR23220:SF4; INTEGRIN ALPHA-V; 1. DR Pfam; PF01839; FG-GAP; 3. DR Pfam; PF08441; Integrin_A_Ig_1; 1. DR Pfam; PF20805; Integrin_A_Ig_2; 1. DR Pfam; PF20806; Integrin_A_Ig_3; 1. DR Pfam; PF00357; Integrin_alpha; 1. DR PRINTS; PR01185; INTEGRINA. DR SMART; SM00191; Int_alpha; 5. DR SUPFAM; SSF69318; Integrin alpha N-terminal domain; 1. DR SUPFAM; SSF69179; Integrin domains; 3. DR PROSITE; PS51470; FG_GAP; 7. DR PROSITE; PS00242; INTEGRIN_ALPHA; 1. DR Genevisible; P43406; MM. PE 1: Evidence at protein level; KW Angiogenesis; Calcium; Cell adhesion; Cell junction; Cell membrane; KW Cleavage on pair of basic residues; Developmental protein; Differentiation; KW Disulfide bond; Glycoprotein; Integrin; Membrane; Metal-binding; Receptor; KW Reference proteome; Repeat; Signal; Transmembrane; Transmembrane helix. FT SIGNAL 1..30 FT /evidence="ECO:0000250" FT CHAIN 31..1044 FT /note="Integrin alpha-V" FT /id="PRO_0000016304" FT CHAIN 31..885 FT /note="Integrin alpha-V heavy chain" FT /evidence="ECO:0000250" FT /id="PRO_0000016305" FT CHAIN 887..1044 FT /note="Integrin alpha-V light chain" FT /evidence="ECO:0000250" FT /id="PRO_0000016306" FT TOPO_DOM 31..988 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 989..1012 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 1013..1044 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT REPEAT 32..98 FT /note="FG-GAP 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00803" FT REPEAT 109..170 FT /note="FG-GAP 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00803" FT REPEAT 173..225 FT /note="FG-GAP 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00803" FT REPEAT 237..291 FT /note="FG-GAP 4" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00803" FT REPEAT 292..357 FT /note="FG-GAP 5" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00803" FT REPEAT 358..415 FT /note="FG-GAP 6" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00803" FT REPEAT 419..482 FT /note="FG-GAP 7" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00803" FT REGION 1023..1044 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 1015..1019 FT /note="GFFKR motif" FT BINDING 260 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P06756" FT BINDING 262 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P06756" FT BINDING 264 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P06756" FT BINDING 266 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P06756" FT BINDING 268 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P06756" FT BINDING 314 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P06756" FT BINDING 316 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P06756" FT BINDING 318 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P06756" FT BINDING 320 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P06756" FT BINDING 322 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P06756" FT BINDING 379 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000250|UniProtKB:P06756" FT BINDING 381 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000250|UniProtKB:P06756" FT BINDING 383 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000250|UniProtKB:P06756" FT BINDING 385 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000250|UniProtKB:P06756" FT BINDING 387 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000250|UniProtKB:P06756" FT BINDING 443 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000250|UniProtKB:P06756" FT BINDING 445 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000250|UniProtKB:P06756" FT BINDING 447 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000250|UniProtKB:P06756" FT BINDING 449 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000250|UniProtKB:P06756" FT BINDING 451 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000250|UniProtKB:P06756" FT CARBOHYD 74 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19349973, FT ECO:0000269|PubMed:19656770" FT CARBOHYD 290 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 296 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 615 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19349973, FT ECO:0000269|PubMed:19656770" FT CARBOHYD 704 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 835 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 851 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 869 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19349973, FT ECO:0000269|PubMed:19656770" FT CARBOHYD 941 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:19656770" FT CARBOHYD 969 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 976 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 89..97 FT /evidence="ECO:0000250|UniProtKB:P06756" FT DISULFID 138..158 FT /evidence="ECO:0000250|UniProtKB:P06756" FT DISULFID 172..185 FT /evidence="ECO:0000250|UniProtKB:P06756" FT DISULFID 491..502 FT /evidence="ECO:0000250|UniProtKB:P06756" FT DISULFID 508..565 FT /evidence="ECO:0000250|UniProtKB:P06756" FT DISULFID 626..632 FT /evidence="ECO:0000250|UniProtKB:P06756" FT DISULFID 698..711 FT /evidence="ECO:0000250|UniProtKB:P06756" FT DISULFID 852..910 FT /note="Interchain (between heavy and light chains)" FT /evidence="ECO:0000250|UniProtKB:P06756" FT DISULFID 900..905 FT /evidence="ECO:0000250|UniProtKB:P06756" FT CONFLICT 526..527 FT /note="EL -> DV (in Ref. 1; AAC52497)" FT /evidence="ECO:0000305" FT CONFLICT 768..769 FT /note="VL -> EK (in Ref. 1; AAC52497)" FT /evidence="ECO:0000305" FT CONFLICT 872 FT /note="A -> G (in Ref. 1; AAC52497)" FT /evidence="ECO:0000305" FT CONFLICT 880 FT /note="N -> S (in Ref. 1; AAC52497)" FT /evidence="ECO:0000305" FT CONFLICT 887 FT /note="D -> G (in Ref. 1; AAC52497)" FT /evidence="ECO:0000305" SQ SEQUENCE 1044 AA; 115360 MW; 417FD73D776B5918 CRC64; MAAPGRLLLR PRPGGLLLLL PGLLLPLADA FNLDVESPAE YAGPEGSYFG FAVDFFEPST SSRMFLLVGA PKANTTQPGI VEGGQVLKCE CSSSRRCQPI EFDSTGNRDY AKDDPLEFKS HQWFGASVRS KQDKILACAP LYHWRTEMKQ EREPVGTCFL QDGTKTVEYA PCRSKNIDAD GQGFCQGGFS IDFTKADRVL LGGPGSFYWQ GQLISDQVAE IISKYDPNVY SIKYNNQLAT RTAQAIFDDS YLGYSVAVGD FNGDGIEDFV SGVPRAARTL GMVYIYDGKN MSSLHNFTGE QMAAYFGFSV AATDINGDDY ADVFIGAPLF MDRGSDGKLQ EVGQVSVSLQ RAVGDFQTTK LNGFEVFARF GSAIAPLGDL DQDGFNDIAI AAPYGGEDKK GLVYIFNGRS TGLNSVPSQI LEGQWAAQSM PPSFGYSMKG ATDVDRNGYP DLVVGAFGVD RAVLYRARPV VTVNAGLEVY PSILNQDNKI CPLPGTALKV SCFNVRFCLK ADGKGTLPRK LHFQVELLLD KLKQKGAIRR ALFLHNRSPV HSKTMTVFRG GQMQCEELVA YLRDESEFRD KLTPITIFME YRLDQRTAAD ATGLQPILNQ FTPANVSRQA HILLDCGEDN VCKPKLEVSV NSDQKKIYIG DDNPLTLTVK AQNQGEGAYE AELIVSIPPQ ADFIGVVRNN EALARLSCAF KTENQTRQVV CDLGNPMKAG TQLLAGLRFS VHQQSEMDTS VKFDLKIQSS NSFDNVSPVV SYKVDLAVLA AVEIRGVSSP DHIFLPIPNW EYKENPETEE DVGPIVQHIY ELRNNGPSSF SKAILNLQWP YKYNNNTLLY ILHYDIDGPM NCTADTEINP LRIKTPEKND TAAAGQGERN HLITKRDLTL REGDVHTLGC GIAKCLQITC QVGRLDRGKS AILYVKSLLW TETFMNKENQ NHSYSLKSSA SFNIIEFPYK NLPIEDLFNS TLVTTNITWG IQPAPMPVPV WVIILAVLAG LLLLAVLVFV MYRMGFFKRV RPPQEEQERE QLQPHENGEG NSET //